Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) insider Anne Lesage sold 20,000 shares of Pharvaris stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $38.27, for a total value of $765,400.00. Following the completion of the transaction, the insider owned 73,969 shares of the company’s stock, valued at approximately $2,830,793.63. This trade represents a 21.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
Anne Lesage also recently made the following trade(s):
- On Thursday, September 10th, Anne Lesage sold 30,000 shares of Pharvaris stock. The shares were sold at an average price of $38.30, for a total value of $1,149,000.00.
- On Tuesday, June 30th, Anne Lesage sold 30,703 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47.
- On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The stock was sold at an average price of $35.48, for a total transaction of $988,898.56.
- On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total transaction of $245,244.85.
- On Monday, June 29th, Anne Lesage sold 10,600 shares of Pharvaris stock. The shares were sold at an average price of $35.07, for a total transaction of $371,742.00.
Pharvaris Price Performance
Shares of Pharvaris stock traded down $0.35 during trading on Monday, hitting $36.02. The stock had a trading volume of 653,689 shares, compared to its average volume of 412,750. The firm’s fifty day simple moving average is $35.37 and its 200-day simple moving average is $31.75. The stock has a market cap of $2.36 billion, a PE ratio of -11.81 and a beta of -2.33. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $43.25.
Institutional Investors Weigh In On Pharvaris
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in shares of Pharvaris in the 2nd quarter worth $41,000. CoreCap Advisors LLC purchased a new position in Pharvaris during the 2nd quarter valued at about $93,000. Public Employees Retirement System of Ohio purchased a new position in Pharvaris during the 2nd quarter valued at about $196,000. Algert Global LLC bought a new stake in shares of Pharvaris in the 2nd quarter valued at about $238,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Pharvaris in the 2nd quarter valued at about $273,000.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on PHVS. Wedbush increased their price target on Pharvaris from $42.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $75.00 price objective on shares of Pharvaris in a research report on Tuesday, September 8th. UBS Group set a $79.00 target price on Pharvaris in a research note on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research report on Tuesday, September 8th. Finally, Leerink Partners upped their price target on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $59.87.
Get Our Latest Stock Report on Pharvaris
About Pharvaris
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Read More
- Five stocks we like better than Pharvaris
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
